Abstract
Introduction

32
Obesity has been defined as a chronic disease by the Obesity Society (TOS) in 2018 due to its 33 emerging epidemiological trend [1] . It increases the risk of developing other metabolic disorders 34 such as hypertension, type 2 diabetes, cardiovascular diseases and myocardial infarction [2, 3] . At 35 least 2.8 million adults die due to being overweight or obese each year [4] . Globally, over 1.9 billion 36 adults were overweight while more than 650 million adults were obese in 2016 [4] .
37
Currently there is a variety of therapeutic targets available for weight reduction, such as 38 pancreatic lipase, alpha-amylase, glucagon like peptide-1 (GLP-1) receptor and serotonin 2C 39 receptor [5] [6] [7] . Along with the general reduction in use of appetite suppressants which act on the 40 central nervous system (CNS), eg: fenfluramine, d-fenfluramine and rimonabant [5] , drugs that act 41 on the periphery have gained wider use [5] . Some periphery-acting drugs have proven successful in 42 weight management with mild intolerances, especially those which reduce the digestion and 43 absorption of nutrients [6] .
44
In humans, various forms of carbohydrates account for between 40% to 80% of total caloric 45 intake [5, 6] . Low GI foods (GI value < 55), polymeric form of carbohydrates that are absorbed 46 slowly, have been linked to glycemic control and weight loss [8] . An alternative to low GI foods are 47 products that can decrease carbohydrate absorption via suppressing related enzymes such as 48 pancreatic α-amylase [6, 8] . Αlpha-amylase is responsible for catalysing the hydrolysis of α-(1, 49 4)-glycosidic linkages of starch components and glycogen. Therefore, suppressing this enzyme could 50 result in a general decrease of the main dietary carbohydrates absorption [5] . The known 51 alpha-amylase inhibitors such as acarbose have been used as an off-label agent to assist weight loss 52 [9] . In addition, the supplement Phase2 ® Phaseolus vulgaris white bean extract demonstrated 53 weight-loss effects in human clinical trials via its amylase inhibitory activity [10] .
54
Chinese herbal formulas are therapeutic herbs traditionally used in combination rather than 55 individually. Many in vitro and in vivo studies [11] [12] [13] [14] [15] [16] 
107
Fluormetric assay of PPA activity using DQ TM Starch as a substrate was determined using a 108 modified method previously described by [35] . Twenty-five microliters of each individual herbal 109 extract at the final concentration of 300 µ g/mL, the RCM-107 formula extraction (10-800µ g/mL) and 
188
It is worthy to note that RCM-107 is an 8-herb combination at 2:1(w/w) ratio, in which the
189
proportion of green tea is 2-fold higher than the other 7 herbs in this formula, due to its role as a key 
220
In addition, substrate (starch) was docked into the corresponding protein to analyse its 221 ligand-target interactions and how they differ from the known inhibitor. According to the results, all 222 four classes of interactions mentioned earlier present (Figure 3) . However, only one residue formed 223 a H-bond for each of these classes (only Glu233 can be found under the category of H-bond with 224 acidic residues) whereas there are at least 2 residues involved in each interaction for acarbose (eg.
225
Glu233 and Asp300). Amongst these residues, three carboxyl groups Glu233, Asp300 and Asp197 (Table 1) .
276
Conclusion
277
The present work examined the alpha-amylase inhibition of the herbal formula RCM-107 and 278 its constituent herbs, and showed that the RCM-107 can be applied as an effective α-amylase 279 inhibitor, which act in a dose-dependent manner. Marginal (though not statistically significant) 280 synergistic effects were observed for the RCM-107 formula when compared to the 8 single herbs.
281
However, the lack of observable significant synergistic effects may be related to the differences . 3D interactions between predicted leading compounds EGCG (pink), Plantagoside (yellow), the known inhibitor acarbose (red) and 1OSE.
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